natgillin/translations-raw huggingface dataset:
Feltstudierne der blev udført for at vise effekten af vaccinen blev udført i besætninger hvor persistent inficerede dyr var sat ud
The field studies to investigate the efficacy of the vaccine were done in herds where persistently infected animals had been removed.
Feltstyrker fra faste RF-sendere, bestemt ved en elektromagnetisk måling på stedet, a bør ligge under overensstemmelsesniveauet i alle frekvensområder. b
Field strengths from fixed RF transmitters, as determined by an electromagnetic site survey, a should be less than the compliance level in each frequency range. b
Feltundersøgelsen med ektoparasitter viste, at Nexgard Spectra var effektivt til behandling af lopper og flåter hos hunde i indtil 30 dage efter behandlingen.
The ectoparasite field study showed that Nexgard Spectra was effective in treating flea and tick infestations in dogs for up to 30 days after treatment.
Feltundersøgelsen ved indvoldsorm viste, at Nexgard Spectra var effektivt til at reducere indvoldsorm og mindst lige så effektivt som milbemycinoxim og praziquantel.
The field study for gut worms showed that Nexgard Spectra was effective in reducing gut worms and was at least as effective as the milbemycin oxime and praziquantel.
Feltundersøgelsen viste, at Vectra Felis var lige så effektivt som sammenligningsproduktet og nedsatte antallet af lopper med 91 % i løbet af den 84 dage lange undersøgelse.
The field study showed that Vectra Felis was as effective as the comparator product and reduced flea counts by 91% over the 84 day study period.
Feltundersøgelser, der omfattede hjerteorm hos hunde, blev udført både i USA og i Europa.
Field studies involving heartworm in dogs were conducted both in the USA and Europe.
Feltundersøgelserne foregik på et stort antal landbrug i forskellige europæiske lande og omfattede forskellige racer og blandingsracer af svin.
The field studies were carried out on a large number of farms in various European countries involving various breeds and crossbreeds of pigs.
Feltundersøgelserne viste, at vaccination med Porcilis PCV M Hyo nedsatte indholdet af PCV2 i blodet og sværheden af lungeforandringer forårsaget af Mycoplasma hyopneumoniae samt tabet i daglig vægtøgning i opfedningsperioden.
The field studies showed that vaccination with Porcilis PCV M Hyo reduced PCV2 levels in the blood and the severity of lung lesions caused by Mycoplasma hyopneumoniae and the loss of daily weight gain during the finishing period (the fattening period prior to slaughter).
FeLV rekombinant canarypox virus
FeLV recombinant canarypox virus
FeLV rekombinant canarypox virus (vCP97) ................................................................. >107,2 CCID501
FeLV recombinant canarypox virus (vCP97) ................................................................  10 7.2 CCID501
FeLV rekombinant canarypox virus (vCP97) ................................................................. >107,2 CCID501
FeLV recombinant canarypox virus (vCP97) ................................................................  107.2 CCID501.
FeLV rekombinant canarypox virus (vCP97) ..................................................................... >107,2 CCID50
FeLV recombinant canarypox virus (vCP97)...................................................................  107.2 CCID50.
FeLV rekombinant canarypox virus (vCP97) ………………………………………..… >107,2 CCID501
FeLV recombinant canarypox virus (vCP97) ..................................................................  107.2 CCID 1
FeLV rekombinant canarypox virus (vCP97) ………………………………………… >107,2 CCID501
FeLV recombinant canarypox virus (vCP97) ..................................................................  107.2 CCID 1
FeLV-proteinet i vaccinen er ikke udvundet af vira, men fremstilles i en bakterie ved hjælp af ”rekombinant DNA-teknologi”.
The FeLV protein used in the vaccine is not extracted from viruses but is made in a bacterium using ‘recombinant DNA technology’.
Fem (5) patienter responderede, 3
5 patients responded,
Fem af graviditeterne forekom hos kvinder, der vejede over 90 kg.
Five of the pregnancies were in women weighing over 90 kg.
Fem af undersøgelserne var sammenlignende, hvor Zerene blev sammenlignet med placebo (uvirksom behandling) og med zolpidem eller triazolam (andre sovemidler).
Five of these studies were comparative: Zerene was compared with placebo (a dummy treatment) or with zolpidem or triazolam (other medicines used in insomnia).
Fem af undersøgelserne viste ligeledes, at tillægsbehandling med saxagliptin ud over metformin var virkningsfuldt med hensyn til at reducere HbA1c-koncentrationerne.
The five studies on the effects of saxagliptin alone or in combination with metformin also showed that adding saxagliptin to metformin was effective in lowering HbA1c levels.
Fem doseringssprøjter følger med hver pakning Kaletra oral opløsning.
5 dosing syringes are included in each carton of Kaletra oral solution.
Fem forekomster var ikke- alvorlige og 16 forekomster var alvorlige.
Five cases were non-serious and 16 cases were serious.
Fem forsøgspersoner, der var randomiseret til emtricitabin plus tenofovirdisoproxilfumarat, oplevede tab af HbsAg, hvoraf 2 ud af disse 5 forsøgspersoner oplevede serokonversion til anti-HBs.
Five subjects randomised to emtricitabine plus tenofovir disoproxil fumarate experienced HBsAg loss, with 2 of these 5 subjects experiencing seroconversion to anti-HBs.
Fem forsøgspersoner, der var randomiseret til emtricitabin plus tenofovirdisoproxilfumarat, oplevede tab af HbsAg, og 2 ud af disse 5 forsøgspersoner oplevede serokonversion til anti-HBs.
Five subjects randomised to emtricitabine plus tenofovir disoproxil fumarate experienced HBsAg loss, with 2 of these 5 subjects experiencing seroconversion to anti-HBs.
Fem patienter (0,8%) udviklede positive anti-tocilizumab-antistoffer; af disse udviklede alle neutraliserende anti-tocilizumab- antistoffer.
Five patients (0.8%) developed positive anti- tocilizumab antibodies; of these, all developed neutralizing anti-tocilizumab antibodies.
Fem patienter med manglende cirrosestatus i gruppen, der fik SOF+RBV i 24 uger, blev ekskluderet fra denne undergruppeanalyse.
Five patients with missing cirrhosis status in the SOF+RBV 24 week group were excluded from this subgroup analysis.
Fem patienter responderede, 3 komplet og 2 partielt.
5patients responded, 3 completely and 2 partially.
Fem personer indgik i en kohorte med standardbehandling.
Five subjects were enrolled in a standard of care cohort.
Fem procent (3/56) af patienterne uden YMDD-mutationen og 13 procent (11/82) af patienterne med YMDD-mutationen udviste forværring i leverinflammation sammenlignet med præ-behandling.
Five percent (3/56) of patients without the YMDD mutant and 13 % (11/82) of patients with YMDD mutant showed worsening in liver inflammation compared to pre- treatment.
Fem procent af alle patienter fik en IRR ved mere end én infusion.
Five percent of all patients had an IRR at more than one infusion.
Fem ud af de 6 patienter, der blev behandlet med eltrombopag, oplevede TEE ved et trombocyttal > 200.000 pr. µl.
Five of the 6 patients treated with eltrombopag experienced the TEE at a platelet count > 200,000/µl
Fem ud af de seks patienter, der blev behandlet med eltrombopag, oplevede de trombotiske komplikationer ved et trombocyttal > 200.000 pr. µl og inden for 30 dage efter sidste eltrombopag-dosis.
Five of the 6 patients treated with eltrombopag experienced the thrombotic complication at a platelet count > 200,000/µl and within 30 days of the last dose of eltrombopag.
Fem år efter den første injektion af Xiapex var 92,8 % og 93,4 % af personerne seropositive for hhv. anti-AUX-I og anti-AUX-II.
At five years after the initial injection of Xiapex, 92.8% and 93.4% of subjects were seropositive for anti-AUX-I and anti-AUX-II respectively.
Femogtredive procent af patienterne havde et behandlingsregime, som ikke indeholdt tenofovirdisoproxilfumarat.
Thirty-five percent of patients were on a treatment regimen that did not contain tenofovir disoproxil fumarate.
Femten børn i alderen mellem 6 og 18 år og seks børn under 6 år , blev eksponeret for NovoThirteen sammenlagt 393 gange.
Fifteen children between the age of 6 to less than 18 years old and six children less than 6 years old have been treated with NovoThirteen for a total of 393 exposures.
Femten procent (15,0 %) af patienterne i clopidogrel-gruppen og 21,7 % i placebogruppen opnåede det primære endepunkt, hvilket viste en absolut reduktion på 6,7 % og en odds reduktion på 36 % til fordel for clopidogrel (9 5% CI: 24, 47 %; p < 0.001), der hovedsagligt var relateret til en reduktion af infarkt- relaterede okkluderede arterier.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries.
Femten procent (15,0 %) af patienterne i clopidogrel-gruppen og 21,7 % i placebogruppen opnåede det primære endepunkt, hvilket viste en absolut reduktion på 6,7 % og en odds reduktion på 36 % til fordel for clopidogrel (9 5% CI: 24, 47 %; p <0.001), der hovedsagligt var relateret til en reduktion af infarkt- relaterede okkluderede arterier.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries.
Femten procent (15,0 %) af patienterne i clopidogrel-gruppen og 21,7 % i placebogruppen opnåede det primære endepunkt, hvilket viste en absolut reduktion på 6,7 % og en odds reduktion på 36 % til fordel for clopidogrel (95 % CI: 24, 47 %; p < 0,001), der hovedsagligt var relateret til en reduktion af infarkt- relaterede okkluderede arterier.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries.
Femten procent (15,0 %) af patienterne i clopidogrel-gruppen og 21,7 % i placebogruppen opnåede det primære endepunkt, hvilket viste en absolut reduktion på 6,7 % og en odds reduktion på 36 % til fordel for clopidogrel (95 % CI: 24, 47 %; p < 0.001), der hovedsagligt var relateret til en reduktion af infarkt- relaterede okkluderede arterier.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries.
Femten procent (15,0 %) af patienterne i clopidogrelgruppen og 21,7 % i placebogruppen opnåede det primære endepunkt, hvilket viste en absolut reduktion på 6,7 % og en oddsreduktion på 36 % til fordel for clopidogrel (95 % CI: 24, 47 %; p<0,001), der hovedsagligt var relateret til en reduktion af infarkt-relaterede okkluderede arterier.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries.
Femten ud af 120 (13%) patienter i REYATAZ + ritonavir-behandlingsarmen og 17 ud af 123 (14%) patienter i lopinavir + ritonavir- armen havde fire eller flere af PI-substitutionerne L10, M46, I54, V82, I84 og L90.
Fifteen of 120 (13%) patients in the REYATAZ + ritonavir treatment arm and 17 of 123 (14%) patients in the lopinavir + ritonavir arm had four or more of the PI substitutions L10, M46, I54, V82, I84, and L90.
Femten ud af 36 (41,7 %) patienter havde gennemgået allogen HSCT, inden de fik BLINCYTO.
Fifteen of 36 (41.7%) patients had undergone allogeneic HSCT prior to receiving BLINCYTO.
Femurkondylet er enden af lårbenet, der udgør en del af dit knæ.
The femoral condyle is the end of the thigh bone, which forms part of your knee.
Femårs-estimaterne for OS var 74 % for dinutuximab-immunterapi sammenlignet med 57 % for isotretinoin alene (log-rank test p = 0,030).
The 5 year estimates of OS were 74 % for dinutuximab immunotherapy compared to 57 % for isotretinoin alone (log-rank test p = 0.030).
Fenbendazol 200 mg
Fenbendazole 200 mg
Fendrix er en hvid, mælkeagtig suspension i en fyldt injektionssprøjte (0,5 ml).
Fendrix is a white, milky suspension presented in a glass prefilled syringe (0.5 ml).
Fendrix er en vaccine, som forebygger sygdommen hepatitis B. Den bruges til patienter med nedsat nyrefunktion:
Fendrix is a vaccine which prevents hepatitis B. It is used for patients with kidney problems:
Fendrix fås i pakninger med 1 injektionssprøjte med eller uden separat nål og i en pakning med 10 injektionssprøjter uden nåle.
Fendrix is available in packs of 1 (with or without a separate needle) and in a pack size of 10 without needles.
Fendrix indeholder små mængder proteiner fra hepatitis B- virussets overflade (‘overfladeantigen’).
Fendrix contains small amounts of the ‘surface antigen’ (proteins from the surface) of the hepatitis B virus.
Fendrix inducerer specifikke humorale antistoffer mod HBsAg (anti-HB-antistoffer).
Fendrix induces specific humoral antibodies against HBsAg (anti-HBs antibodies).
Fendrix injektionsvæske, suspension
Fendrix suspension for injection
Fendrix injektionsvæske, suspension i.m.
Fendrix suspension for injection IM
Fendrix kan ikke forhindre, at du bliver syg, hvis du allerede er smittet med hepatitis B-virus.
Fendrix may not protect you from being ill if you have already caught the hepatitis B virus.
Fendrix kan kun beskytte dig mod infektion med hepatitis B-virus.
Fendrix can only help to protect you against infection with the hepatitis B virus.
Fendrix må ikke gives til personer med akut alvorlig febril lidelse.
Fendrix should not be given to subjects suffering from acute severe febrile illness.
Fendrix må ikke gives til personer, der har vist sig overfølsomme for andre hepatitis B-vacciner
Fendrix should not be given to subjects with hypersensitivity after previous administration of other hepatitis B vaccines.
Fendrix må under ingen omstændigheder injiceres intradermalt eller intravenøst.
Fendrix should under no circumstances be administered intradermally or intravenously.
Fendrix skal injiceres intramuskulært i deltoidea-regionen.
Fendrix should be injected intramuscularly in the deltoid region.
fenfluramin (til vægtreduktion) tritoqualin (til behandling af allergier)
fenfluramine (to reduce weight) tritoqualine (to treat allergies)
fenfluramin pentoxifyllin (høje parenterale doser) fibrater tritoqualin
fenfluramine, pentoxifylline (high dose parenteral), fibrates, tritoqualine,
fenobarbital (anvendes til behandling af epilepsi) fenytoin (anvendes til behandling af epilepsi)
phenobarbital (used to treat epilepsy) phenytoin (used to treat epilepsy)
Fenofibrat er en "PPAR-agonist".
Fenofibrate is a ‘PPAR agonist’.
Fenofibrat er en “PPAR-agonist”.
Fenofibrate is a ‘PPAR agonist’.
Fenofibrat og simvastatin er ikke CYP 3A4-hæmmere eller -inducere.
Fenofibrate and simvastatin are not CYP 3A4 inhibitors or inducers.
Fenofibrinsyre bindes stærkt til plasmaalbumin (over 99 %).
Fenofibric acid is strongly bound to plasma albumin (more than 99%).
Fenofibrinsyre elimineres ikke ved hæmodialyse.
Fenofibric acid is not eliminated by haemodialysis.
Fenothiazider (bruges til at behandle psykiske lidelser eller kvalme og opkastning),
phenothiazines (used to treat psychiatric disorders, or nausea and vomiting),
Fentanyl (5 g/kg enkelt- dosis)
Fentanyl (5 µg/kg single dose)
Fentanyl absorberes hurtigt fra din næse til blodomløbet.
Fentanyl is absorbed quickly through the lining of your nose and into the blood stream.
Fentanyl bevæger sig gradvist gennem huden og ind i din hunds blodstrøm og virker dernæst smertestillende.
Fentanyl gradually moves through the skin into your dog’s bloodstream and then relieves pain.
Fentanyl bør ikke anvendes af ammende kvinder, og amning bør ikke genoptages før mindst 5 dage efter den sidste dosis fentanyl.
Fentanyl should not be used by breastfeeding women and breastfeeding should not be restarted until at least 5 days after the last administration of fentanyl.
Fentanyl er et opioidanalgetikum, der overvejende interagerer med opioid-µ-receptoren.
Fentanyl is an opioid analgesic, interacting predominantly with the opioid µ-receptor.
Fentanyl kan passere ind i modermælken og give det ammende barn bivirkninger.
Fentanyl can pass into the breast milk and may cause side effects to the breast-fed child.
Fentanyl metaboliseres i leveren og i tarmenes slimhinder til norfentanyl af CYP3A4- isoformen.
Fentanyl is metabolised in the liver and in the intestinal mucosa to norfentanyl by CYP3A4 isoform.
Fentanyl metaboliseres primært i leveren via CYP3A4.
Fentanyl is metabolised primarily in the liver via CYP3A4.
Fentanyl må ikke anvendes af ammende kvinder, og amning bør ikke genoptages, indtil mindst 5 dage efter den sidste administration af fentanyl.
Fentanyl should not be used by breastfeeding women and breast-feeding should not be restarted until at least 5 days after the last administration of fentanyl.
Fentanyl Ritonavir doseret som en farmakokinetisk forstærker eller som et antiretroviralt stof hæmmer CYP3A4 og forventes som følge heraf at øge plasmakoncentrationerne af fentanyl.
Fentanyl Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of fentanyl.
Fentanyl udskilles i modermælken og kan forårsage sedation og respirationsdepression hos det diende barn.
Fentanyl passes into breast milk and may cause sedation and respiratory depression in the breast-fed child.
Fentanyl udskilles i modermælken og kan medføre sedation og respirationsdepression hos det ammede barn.
Fentanyl passes into breast milk and may cause sedation and respiratory depression in the breast-fed child.
Fentanyl udskilles i modermælken og kan medføre sedation og respirationsdepression hos det ammende barn.
Fentanyl passes into breast milk and may cause sedation and respiratory depression in the breast-fed child.
fentanyl – anvendes til behandling af smerter i forbindelse med kræft
fentanyl – used to treat cancer pain
Fentanyls plasmaproteinbinding er 80 – 85 %.
The plasma protein binding of fentanyl is 80 – 85 %.
Fenylalanin- og tyrosinniveauet i blodet bør især i pædiatriske patienter måles 1-2 uger efter hver dosisjustering og efterfølgende monitoreres hyppigt under ledelse af den behandlende læge.
Blood phenylalanine and tyrosine levels should be tested, particularly in children, one to two weeks after each dose adjustment and monitored frequently thereafter, under the direction of the treating physician.
Fenylalaninniveauet i blodet bør måles inden initiering af behandling og efter 1 uges behandling med Kuvan med den anbefalede initialdosis.
Blood phenylalanine levels should be checked before initiating treatment and after 1 week of treatment with Kuvan at the recommended starting dose.
fenylbutazon, azapropazon og oxyfenbutazon sulfinpyrazon
phenylbutazone, azapropazon and oxyfenbutazone, sulphinpyrazone,
fenytoin eller fenobarbital, der anvendes til behandling af epilepsi
phenytoin or phenobarbital, used to treat epilepsy
fenytoin og fenobarbital til behandling af epilepsi
phenytoin or phenobarbital, used to treat epilepsy
Fenytoin, carbamazepin og barbiturater - anvendes til behandling af epilepsi
Phenytoin, carbamazepine and barbiturates - used to treat epilepsy
fenytoin, diazoxid glucagon, barbiturater og rifampicin acetozolamid
phenytoin, diazoxide, glucagon, barbiturates and rifampicin, acetozolamide.
Feraccru anvendes hos voksne med inflammatorisk tarmsygdom til behandling af lavt indhold af jern i kroppen.
Feraccru is used in adults with inflammatory bowel disease (IBD) to treat low iron stores in your body.
Feraccru bør ikke anvendes til patienter med eksacerbation af aktiv inflammatorisk tarmsygdom (IBD) eller IBD- patienter med niveauer af hæmoglobin (Hb) under 9,5 g/dl.
Feraccru should not be used in patients with inflammatory bowel disease (IBD) flare or in IBD- patients with haemoglobin (Hb) <9.5 g/dl.
Feraccru er et lægemiddel, der indeholder jern.
Feraccru is an iron-containing medicine.
Feraccru er påvist at være effektivt til at forøge hæmoglobinet hos patienter med kronisk tarmbetændelsen og jernmangelanæmi.
Feraccru has been shown to be effective in increasing haemoglobin levels in patients with inflammatory bowel disease and iron deficiency anaemia.
Feraccru er røde hårde kapsler, der indeholder et rødbrunt pulver.
Feraccru is a red hard capsule containing a reddish-brown powder.
Feraccru ferrimaltol
Feraccru ferric maltol
Feraccru forventes ikke at påvirke evnen til at føre motorkøretøj bil eller betjene maskiner.
Feraccru is unlikely to have any effect on the ability to drive and use machines.
Feraccru indeholder:
What Feraccru contains
Feraccru, hårde kapsler, 30 mg
Feraccru 30 mg hard capsules
Feraccru, hårde kapsler, 30 mg Jern (som ferrimaltol)
Feraccru 30 mg hard capsules Iron (as ferric maltol)
Feraccru-kapsler indeholder lactose, Sunset Yellow (E110) og Allura Red (E129).
Feraccru capsules contain lactose, Sunset Yellow FCF (E110) and Allura Red AC (E129).
Feraccrus sikkerhed og virkning ved behandling af jernmangelanæmi blev undersøgt hos 128 patienter (alder 18-76 år; 45 mænd og 83 kvinder) med inaktiv til let aktiv irritabel tarmsygdom (58 patienter med colitis ulcerosa og 70 patienter med Crohns sygdom) og baselinekoncentrationer af Hb på mellem 9,5 g/dL og 12 / 13 g/dL for kvinder / mænd.
The safety and efficacy of Feraccru for the treatment of iron deficiency anaemia was studied in 128 patients (age range 18-76 years; 45 males and 83 females) with inactive to mildly active IBD (58 patients with Ulcerative Colitis [UC] and 70 patients with Crohn’s disease [CD]) and baseline Hb concentrations between 9.5 g/dL and 12 / 13 g/dL for females / males.
Fermentering: Eli Lilly and Company, Lilly Technology Center Building 333 and 324, Indianapolis, Indiana, USA
Fermentation: Eli Lilly and Company, Lilly Technology Center Building 333 and 324, Indianapolis, Indiana, USA
Ferrer Internacional, S.A. Spanien
Ferrer Internacional, S.A. Spain
Ferring Arzneimittel GmbH Tel: + 49-(0)431-5852 0
Ferring Arzneimittel GmbH Tel: + 49-(0)431-5852 0 info-service@ferring.de
Ferring Arzneimittel GmbH Tel: +49 431 5852 0
Ferring Arzneimittel GmbH Tel: +49 431 5852 0 info-service@ferring.de
Ferring Pharmaceuticals SA Reprezentanţa în România Tel: + 40356 113 270
Ferring Pharmaceuticals SA Reprezentanţa în România Tel: +40 356 113 270
Ferriprox 100 mg/ml oral opløsning
Ferriprox 100 mg/ml oral solution
Ferriprox 100 mg/ml oral opløsning deferipron
Ferriprox 100 mg/ml oral solution Deferiprone
Ferriprox 1000 mg filmovertrukne tabletter 3 år.
Ferriprox 1000 mg film-coated tablets 3 years.
Ferriprox 1000 mg tabletter er hvide til off-white, kapselformede, filmovertrukne tabletter påtrykt “APO” på den ene halvdel og “1000” på den anden, uden påtryk på bagsiden.
Ferriprox 1000 mg tablets are white to off-white, capsule-shaped, film-coated tablets imprinted “APO” bisect “1000” on one side, plain on the other.
Ferriprox 500 mg filmovertrukne tabletter 5 år.
Ferriprox 500 mg film-coated tablets 5 years.
Ferriprox 500 mg filmovertrukne tabletter EU/1/99/108/001
Ferriprox 500 mg film-coated tablets EU/1/99/108/001
Ferriprox 500 mg filmovertrukne tabletter Ferriprox 1000 mg filmovertrukne tabletter
Ferriprox 500 mg film-coated tablets Ferriprox 1000 mg film-coated tablets
Ferriprox 500 mg filmovertrukne tabletter Hver tablet indeholder 500 mg deferipron.
Ferriprox 500 mg film-coated tablets Each tablet contains 500 mg deferiprone.